T1	Participants 58 110	patients with relapsing-remitting multiple sclerosis
T2	Participants 614 752	Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI.
T3	Participants 779 815	306 eligible patients were enrolled.
T4	Participants 816 842	Patients, aged 18-50 years
